CAMZYOS is the first and only cardiac myosin
inhibitor approved in the European Union
Approval based on two positive Phase 3
trials, EXPLORER-HCM and VALOR-HCM, demonstrating significant
benefit in patients treated with CAMZYOS versus placebo
Bristol Myers Squibb (NYSE: BMY) today announced that the
European Commission (EC) has approved CAMZYOS® (mavacamten, 2.5 mg,
5 mg, 10 mg, 15 mg capsules) for the treatment of symptomatic (New
York Heart Association, NYHA, class II-III) obstructive
hypertrophic cardiomyopathy (HCM) in adult patients. CAMZYOS is the
first and only allosteric and reversible inhibitor selective for
cardiac myosin approved in all European Union (EU) member states*
and is the first cardiac myosin inhibitor that targets the
underlying pathophysiology of HCM. The EC approval of CAMZYOS is
based upon positive efficacy and safety results from two Phase 3
trials, EXPLORER-HCM and VALOR-HCM.
“This approval marks an important milestone for patients in
Europe who will now have a therapeutic option in CAMZYOS, a
first-in-class cardiac myosin inhibitor that treats the underlying
pathophysiology of symptomatic obstructive HCM,” said Samit
Hirawat, M.D., chief medical officer, Bristol Myers Squibb. “We’re
proud to bring this innovative treatment to more patients around
the world, while reinforcing our ongoing dedication to transforming
patients’ lives through science on a global scale.”
Symptomatic obstructive HCM is an often-inherited heart disease
that can be a chronic, debilitating, and progressive condition
where patients may experience symptoms of shortness of breath,
dizziness and fatigue as well as serious, life-altering
complications, including heart failure, arrhythmias, stroke and in
rare cases (~1%), sudden cardiac death.
“Obstructive HCM is a life-changing disease for many patients
who suffer from symptoms that can significantly impact their
quality of life. The positive results of both Phase 3 clinical
trials showed that CAMZYOS demonstrated efficacy across all primary
and secondary endpoints, including improvements in exercise
capacity and symptom burden for these patients,” said Iacopo
Olivotto, M.D., Professor of Cardiology at the University of
Florence and Head of Cardiology at Meyer Children's Hospital,
Florence, Italy. “As the lead clinical investigator for
EXPLORER-HCM, I am grateful to the patients who played a key role
in this approval and look forward to having CAMZYOS available to
patients in the EU who have long awaited a new treatment option for
this chronic disease.”
Please see important safety information, including Boxed
WARNING, from the U.S. prescribing information below.
Bristol Myers Squibb thanks the patients and investigators
involved in both clinical trials.
*Centralized Marketing Authorization does not include approval
in Great Britain (England, Scotland, Wales).
Full European Summary of Product Characteristics for CAMZYOS is
available from the EMA website at www.ema.europa.eu.
About EXPLORER-HCM
The EXPLORER-HCM Phase 3 trial (NCT03470545) was a double-blind,
randomized, placebo-controlled, parallel group trial that enrolled
a total of 251 adult patients with symptomatic (NYHA class II or
III), obstructive hypertrophic cardiomyopathy. All participants had
measurable left ventricular ejection fraction (LVEF) ≥55% and at
least one peak LVOT gradient ≥50 mmHg (at rest or with provocation
at diagnosis); in addition, Valsalva LVOT gradient ≥30 mmHg at
baseline was required at screening. Ninety-two percent of patients
were on background therapies of a beta blocker or calcium channel
blocker. At baseline, approximately 73% of the randomized patients
were NYHA class II and 27% were NYHA class III. The mean LVEF was
74%, and the mean Valsalva left ventricular outflow tract (LVOT)
gradient was 73 mmHg. The baseline mean Kansas City Cardiomyopathy
Questionaire-23 (KCCQ-23) Clinical Summary Score (CSS) was 71.
The primary endpoint was a composite functional endpoint,
assessed at 30 weeks, and was defined as the proportion of patients
who achieved either improvement of mixed venous oxygen tension
(pVO2) by ≥1.5 mL/kg/min plus improvement in NYHA class by at least
1 or improvement of pVO2 by ≥3.0 mL/kg/min plus no worsening in
NYHA class. Key secondary endpoints include impact on exercise
gradient LVOT, pVO2, NYHA Class and Kansas City Cardiomyopathy
Questionnaire (KCCQ)* and Hypertrophic Cardiomyopathy Symptom
Questionnaire (HCMSQ)† at Week 30.
The trial met all primary and secondary endpoints with
statistical significance:
- At Week 30, 37% (n=45/123) of patients taking CAMZYOS achieved
the composite primary endpoint, defined as the proportion of
patients who achieved either improvement of mixed venous oxygen
tension (pVO2) by ≥1.5 mL/kg/min plus improvement in NYHA class by
at least 1 or improvement of pVO2 by ≥3.0 mL/kg/min plus no
worsening in NYHA class, versus 17% (n=22/128) treated with
placebo. The difference was 19.4% (95% CI: 8.67, 30.13;
p=0.0005).
- Additionally at Week 30, patients receiving CAMZYOS had greater
improvement compared to placebo group across all secondary
endpoints, including:
- Change from baseline post-exercise LVOT peak gradient [-47 mmHg
vs -10 mmHg; -35 difference (95% CI: -43, -28; p<0.0001)]
- Change from baseline in pVO2 [1.4 mL/kg/min vs -0.05 mL/kg/min;
1.4 difference (95% CI: 0.6, 2; p<0.0006)]
- Number (%) of patients with improvement of NYHA class ≥1 [80
(65%) vs 40 (31%); difference of 34% (95% CI; 22%, 45%;
p<0.0001)]
- Change from baseline in KCCQ-23 CSS [14 vs 4; difference of 9
(95% CI: 5, 13); p<0.0001]
- Change from baseline in HCMSQ SoB domain score [-2.8 vs -0.9;
difference of -1.8 (95% CI: -2.4, -1.2); p<0.0001]
* The KCCQ-23 CSS is derived from the Total Symptoms Score (TSS)
and the Physical Limitations (PL) score of the KCCQ-23. The CSS
ranges from 0 to 100, with higher scores representing better health
status.
† The HCMSQ SoB domain score measures frequency and severity of
shortness of breath. The domain score ranges from 0 to 18, with
lower scores representing less shortness of breath.
About VALOR-HCM
VALOR-HCM (NCT04349072) was a randomized, double-blind,
placebo-controlled, multicenter Phase 3 study of patients with
symptomatic, obstructive HCM (NYHA class II-IV) who met guideline
criteria for septal reduction therapy (SRT; LVOT gradient of ≥50
mmHg and NYHA class III-IV, or class II with exertional syncope or
near syncope) and had been referred or under active consideration
(within the past 12 months) for an invasive procedure. The study
enrolled 112 patients (mean age of 60 years; 51% men; 93% ≥NYHA
class III) randomized on a 1:1 basis to receive mavacamten or
placebo. At baseline, 95% of patients were on background therapies
of a beta blocker, calcium channel blocker, disopyramide or a
combination. The primary endpoint was a composite of the proportion
of patients who decided to proceed with SRT prior to or at Week 16
or who remained SRT-guideline eligible (LVOT gradient of ≥50 mmHg
and NYHA Class III-IV, or Class II with exertion induced syncope or
near syncope) at Week 16. Key secondary endpoints included the
change from baseline on exercise gradient LVOT, NYHA Class and
Kansas City Cardiomyopathy Questionnaire (KCCQ) and biomarkers at
Week 16.
The trial met all primary and secondary endpoints with
statistical significance:
- Results showed that CAMZYOS significantly reduced the primary
composite endpoint of patient decision to proceed with SRT prior to
or at Week 16 or patients who remain SRT eligible (LVOT gradient of
≥50 mmHg and NYHA class III-IV, or class II with exertional syncope
or near syncope) at Week 16, with 82% of patients no longer
eligible for the surgical procedure or deciding not to proceed with
SRT after 16 weeks of treatment. Only 10 (17.9%) patients treated
with CAMZYOS vs 43 (76.8%) patients in the placebo group decided to
proceed with SRT prior to or at Week 16 or were SRT-eligible at
Week 16; treatment difference (95% CI), 58.9% (44.0%, 73.9%);
p<0.0001.
- Results also showed CAMZYOS met secondary endpoints (change
from baseline to Week 16) vs the placebo group of:
- Change from baseline post-exercise LVOT peak gradient [-39.1
mmHg vs -1.8 mmHg; -37.2 mmHg difference (95% CI: -48.1, -26.2),
p<0.0001]
- Proportion with NYHA Class improvement of at least 1 class
[62.5% vs 21.4%; 41.1% difference (95% CI: 24.5%, 57.7%),
p<0.0001]
- Change from baseline in KCCQ-23 CSS [10.4 vs 1.8; difference of
9.5 (95% CI: 4.9, 14), p<0.0001]
- Change from baseline in N-terminal pro-brain natriuretic
peptide (NT-proBNP) [0.35 vs 1.13; difference of 0.33 (95% CI:
0.27, 0.42), p<0.0001]
- Change from baseline in Cardiac Troponin I [0.5 vs 1.03;
difference of 0.53 (95% CI: 0.41, 0.70), p<0.0001]
EXPLORER-HCM and VALOR-HCM Pooled
Safety Data
The most commonly reported adverse reactions of the 179 patients
treated with CAMZYOS in two Phase 3 studies were dizziness (17%),
dyspnoea (12%), systolic dysfunction (5%) and syncope (5%). In
these clinical studies, 5% (9/179) of patients in the CAMZYOS group
experienced reversible reductions in LVEF <50% (median 45%:
range: 35-49%) while on treatment. In 56% (5/9) of these patients,
reductions were observed without other clinical manifestations. In
all patients treated with CAMZYOS, LVEF recovered following
interruption of CAMZYOS and they completed the study on treatment.
Dyspnoea was reported in 12.3% of patients treated with CAMZYOS
compared to 8.7% of patients on placebo. In the EXPLORER-HCM study,
most (67%) of the dyspnoea events were reported after CAMZYOS was
discontinued, with median time to onset of 2 weeks (range: 0.1-4.9)
after last dose.
About CAMZYOS
(mavacamten)
CAMZYOS (mavacamten) is the first and only cardiac myosin
inhibitor approved in the U.S., indicated for the treatment of
adults with symptomatic New York Heart Association (NYHA) class
II-III obstructive hypertrophic cardiomyopathy (HCM) to improve
functional capacity and symptoms. It has also received regulatory
approvals in Australia, Canada, Brazil, Switzerland, Macau, South
Korea and Singapore. CAMZYOS is an allosteric and reversible
inhibitor selective for cardiac myosin. CAMZYOS modulates the
number of myosin heads that can enter “on actin” (power-generating)
states, thus reducing the probability of force-producing (systolic)
and residual (diastolic) cross-bridge formation. Excess myosin
actin cross-bridge formation and dysregulation of the super-relaxed
state are mechanistic hallmarks of HCM. CAMZYOS shifts the overall
myosin population towards an energy-sparing, recruitable,
super-relaxed state. In HCM patients, myosin inhibition with
CAMZYOS reduces dynamic LVOT obstruction and improves cardiac
filling pressures.
About Obstructive Hypertrophic
Cardiomyopathy
Obstructive hypertrophic cardiomyopathy (obstructive HCM) is a
chronic, progressive disease in which excessive contraction of the
heart muscle and reduced ability of the left ventricle to fill can
make it difficult for blood to circulate to the rest of the body,
leading to the development of debilitating symptoms and cardiac
dysfunction. HCM can be hereditary and can develop at any age.
Patients are typically diagnosed in their 40s or 50s, and as many
as 50% of patients have a hereditary predisposition.
In obstructive HCM, which is the most common type of HCM, the
left ventricular outflow tract (LVOT) where blood leaves the heart
becomes obstructed by the enlarged heart muscle. As a result,
obstructive HCM has also been associated with increased risks of
atrial fibrillation, stroke, heart failure and, although rare,
sudden cardiac death. The most frequent cause of obstructive HCM is
mutations in the heart muscle proteins of the sarcomere.
Obstructive HCM is estimated to affect 400,000-600,000 people
worldwide, however many patients remain undiagnosed and/or
asymptomatic.
About CAMZYOS REMS
Program
CAMZYOS is only available in the U.S. through a restricted
program called the CAMZYOS REMS Program because of the risk of
heart failure due to systolic dysfunction. Further information is
available at www.CAMZYOSREMS.com or by telephone at
1-833-628-7367.
U.S. INDICATION
CAMZYOS (mavacamten) is indicated for the treatment of adults
with symptomatic New York Heart Association (NYHA) class II-III
obstructive hypertrophic cardiomyopathy (HCM) to improve functional
capacity and symptoms.
U.S. IMPORTANT SAFETY
INFORMATION
WARNING: RISK OF HEART FAILURE
CAMZYOS reduces left ventricular ejection fraction (LVEF) and
can cause heart failure due to systolic dysfunction.
Echocardiogram assessments of LVEF are required prior to and
during treatment with CAMZYOS. Initiation of CAMZYOS in patients
with LVEF <55% is not recommended. Interrupt CAMZYOS if LVEF is
<50% at any visit or if the patient experiences heart failure
symptoms or worsening clinical status.
Concomitant use of CAMZYOS with certain cytochrome P450
inhibitors or discontinuation of certain cytochrome P450 inducers
may increase the risk of heart failure due to systolic dysfunction;
therefore, the use of CAMZYOS is contraindicated with the
following:
- Moderate to strong CYP2C19 inhibitors or strong CYP3A4
inhibitors
- Moderate to strong CYP2C19 inducers or moderate to strong
CYP3A4 inducers
Because of the risk of heart failure due to systolic
dysfunction, CAMZYOS is available only through a restricted program
under a Risk Evaluation and Mitigation Strategy (REMS) called the
CAMZYOS REMS PROGRAM.
CONTRAINDICATIONS
CAMZYOS is contraindicated with concomitant use of:
- Moderate to strong CYP2C19 inhibitors or strong CYP3A4
inhibitors
- Moderate to strong CYP2C19 inducers or moderate to strong
CYP3A4 inducers
WARNINGS AND PRECAUTIONS
Heart Failure
CAMZYOS reduces systolic contraction and can cause heart failure
or totally block ventricular function. Patients who experience a
serious intercurrent illness (e.g., serious infection) or
arrhythmia (e.g., atrial fibrillation or other uncontrolled
tachyarrhythmia) are at greater risk of developing systolic
dysfunction and heart failure.
Assess the patient’s clinical status and LVEF prior to and
regularly during treatment and adjust the CAMZYOS dose accordingly.
New or worsening arrhythmia, dyspnea, chest pain, fatigue,
palpitations, leg edema, or elevations in N-terminal pro-B-type
natriuretic peptide (NT-proBNP) may be signs and symptoms of heart
failure and should also prompt an evaluation of cardiac
function.
Asymptomatic LVEF reduction, intercurrent illnesses, and
arrhythmias require additional dosing considerations.
Initiation of CAMZYOS in patients with LVEF <55% is not
recommended. Avoid concomitant use of CAMZYOS in patients on
disopyramide, ranolazine, verapamil with a beta blocker, or
diltiazem with a beta blocker as these medications and combinations
increase the risk of left ventricular systolic dysfunction and
heart failure symptoms and clinical experience is limited.
CYP 450 Drug Interactions Leading to Heart Failure or Loss of
Effectiveness
CAMZYOS is primarily metabolized by CYP2C19 and CYP3A4 enzymes.
Concomitant use of CAMZYOS and drugs that interact with these
enzymes may lead to life-threatening drug interactions such as
heart failure or loss of effectiveness.
Advise patients of the potential for drug interactions,
including with over-the-counter medications (such as omeprazole,
esomeprazole, or cimetidine). Advise patients to inform their
healthcare provider of all concomitant products prior to and during
CAMZYOS treatment.
CAMZYOS Risk Evaluation and Mitigation Strategy (REMS)
Program
CAMZYOS is only available through a restricted program called
the CAMZYOS REMS Program because of the risk of heart failure due
to systolic dysfunction. Notable requirements of the CAMZYOS REMS
Program include the following:
- Prescribers must be certified by enrolling in the REMS
Program.
- Patients must enroll in the REMS Program and comply with
ongoing monitoring requirements.
- Pharmacies must be certified by enrolling in the REMS Program
and must only dispense to patients who are authorized to receive
CAMZYOS.
- Wholesalers and distributors must only distribute to certified
pharmacies.
Further information is available at www.CAMZYOSREMS.com or by
telephone at 1-833-628-7367.
Embryo-Fetal Toxicity
CAMZYOS may cause fetal toxicity when administered to a pregnant
female, based on animal studies. Confirm absence of pregnancy in
females of reproductive potential prior to treatment and advise
patients to use effective contraception during treatment with
CAMZYOS and for 4 months after the last dose. CAMZYOS may reduce
the effectiveness of combined hormonal contraceptives (CHCs).
Advise patients using CHCs to use an alternative contraceptive
method that is not affected by CYP 450 enzyme induction or to add
nonhormonal contraception. Advise females of reproductive potential
about the potential risk to the fetus with maternal exposure to
CAMZYOS during pregnancy.
ADVERSE REACTIONS
In the EXPLORER-HCM trial, adverse reactions occurring in >5%
of patients and more commonly in the CAMZYOS group than in the
placebo group were dizziness (27% vs 18%) and syncope (6% vs 2%).
There were no new adverse reactions identified in VALOR-HCM.
Effects on Systolic Function
In the EXPLORER-HCM trial, mean (SD) resting LVEF was 74% (6) at
baseline in both treatment groups. Mean (SD) absolute change from
baseline in LVEF was -4% (8) in the CAMZYOS group and 0% (7) in the
placebo group over the 30-week treatment period. At Week 38,
following an 8-week interruption of trial drug, mean LVEF was
similar to baseline for both treatment groups. In the EXPLORER-HCM
trial, 7 (6%) patients in the CAMZYOS group and 2 (2%) patients in
the placebo group experienced reversible reductions in LVEF <50%
(median 48%: range 35-49%) while on treatment. In all 7 patients
treated with CAMZYOS, LVEF recovered following interruption of
CAMZYOS.
DRUG INTERACTIONS
Potential for Other Drugs to Affect Plasma Concentrations of
CAMZYOS
CAMZYOS is primarily metabolized by CYP2C19 and to a lesser
extent by CYP3A4 and CYP2C9. Inducers and inhibitors of CYP2C19 and
moderate to strong inhibitors or inducers of CYP3A4 may affect the
exposures of CAMZYOS.
Impact of Other Drugs on
CAMZYOS:
- Moderate to Strong CYP2C19 Inhibitors or Strong CYP3A4
Inhibitors: Concomitant use increases CAMZYOS exposure, which may
increase the risk of heart failure due to systolic dysfunction.
Concomitant use is contraindicated.
- Moderate to Strong CYP2C19 Inducers or Moderate to Strong
CYP3A4 Inducers: Concomitant use decreases CAMZYOS exposure, which
may reduce CAMZYOS’ efficacy. The risk of heart failure due to
systolic dysfunction may increase with discontinuation of these
inducers as the levels of induced enzyme normalizes. Concomitant
use is contraindicated.
- Weak CYP2C19 Inhibitors or Moderate CYP3A4 Inhibitors:
Concomitant use with a weak CYP2C19 inhibitor or a moderate CYP3A4
inhibitor increases CAMZYOS exposure, which may increase the risk
of adverse drug reactions. Initiate CAMZYOS at the recommended
starting dose of 5 mg orally once daily in patients who are on
stable therapy with a weak CYP2C19 inhibitor or a moderate CYP3A4
inhibitor. Reduce dose of CAMZYOS by one level (i.e., 15 to 10 mg,
10 to 5 mg, or 5 to 2.5 mg) in patients who are on CAMZYOS
treatment and intend to initiate a weak CYP2C19 inhibitor or a
moderate CYP3A4 inhibitor. Schedule clinical and echocardiographic
assessment 4 weeks after inhibitor initiation, and do not
up-titrate CAMZYOS until 12 weeks after inhibitor initiation. Avoid
initiation of concomitant weak CYP2C19 and moderate CYP3A4
inhibitors in patients who are on stable treatment with 2.5 mg of
CAMZYOS because a lower dose is not available.
Potential for CAMZYOS to Affect Plasma Concentrations of
Other Drugs
CAMZYOS is an inducer of CYP3A4, CYP2C9, and CYP2C19.
Concomitant use with CYP3A4, CYP2C19, or CYP2C9 substrates may
reduce plasma concentration of these drugs. Closely monitor when
CAMZYOS is used in combination with CYP3A4, CYP2C19, or CYP2C9
substrates where decreases in the plasma concentration of these
drugs may reduce their activity.
Hormonal Contraceptives: Progestin and ethinyl estradiol are
CYP3A4 substrates. Concomitant use of CAMZYOS may decrease
exposures of ethinyl estradiol and progestin, which may lead to
contraceptive failure or an increase in breakthrough bleeding.
Advise patients to use a contraceptive method that is not affected
by CYP 450 enzyme induction (e.g., intrauterine system) or add
nonhormonal contraception (such as condoms) during concomitant use
and for 4 months after the last dose of CAMZYOS.
Drugs That Reduce Cardiac Contractility
Expect additive negative inotropic effects of CAMZYOS and other
drugs that reduce cardiac contractility. Avoid concomitant use of
CAMZYOS in patients on disopyramide, ranolazine, verapamil with a
beta blocker, or diltiazem with a beta blocker as these medications
and combinations increase the risk of left ventricular systolic
dysfunction and heart failure symptoms and clinical experience is
limited.
If concomitant therapy with a negative inotrope is initiated, or
if the dose of a negative inotrope is increased, monitor LVEF
closely until stable doses and clinical response have been
achieved.
SPECIFIC POPULATIONS
Pregnancy
CAMZYOS may cause fetal harm when administered to a pregnant
female. Advise pregnant females about the potential risk to the
fetus with maternal exposure to CAMZYOS during pregnancy. There is
a pregnancy safety study for CAMZYOS. If CAMZYOS is administered
during pregnancy, or if a patient becomes pregnant while receiving
CAMZYOS or within 4 months after the last dose of CAMZYOS,
healthcare providers should report CAMZYOS exposure by contacting
Bristol Myers Squibb at 1-800-721-5072 or www.bms.com.
Lactation
The presence of CAMZYOS in human or animal milk, the drug’s
effects on the breastfed infant, or the effects on milk production
are unknown. The developmental and health benefits of breastfeeding
should be considered along with the mother’s clinical need for
CAMZYOS and any potential adverse effects on the breastfed child
from CAMZYOS or from the underlying maternal condition.
Females and Males of Reproductive Potential
Confirm absence of pregnancy in females of reproductive
potential prior to initiation of CAMZYOS. Advise females of
reproductive potential to use effective contraception during
treatment with CAMZYOS and for 4 months after the last dose. Use of
CAMZYOS may reduce the effectiveness of CHCs. Advise patients using
CHCs to use an alternative contraceptive method or add nonhormonal
contraception.
Please see US Full Prescribing Information, including Boxed
WARNING and Medication Guide.
About Bristol Myers
Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter, YouTube, Facebook and
Instagram.
Cautionary Statement Regarding
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995
regarding, among other things, the research, development and
commercialization of pharmaceutical products. All statements that
are not statements of historical facts are, or may be deemed to be,
forward-looking statements. Such forward-looking statements are
based on current expectations and projections about our future
financial results, goals, plans and objectives and involve inherent
risks, assumptions and uncertainties, including internal or
external factors that could delay, divert or change any of them in
the next several years, that are difficult to predict, may be
beyond our control and could cause our future financial results,
goals, plans and objectives to differ materially from those
expressed in, or implied by, the statements. These risks,
assumptions, uncertainties and other factors include, among others,
that the outcome of pricing and reimbursement negotiations in
individual countries in Europe may delay or limit the commercial
potential of CAMZYOS® (mavacamten) for the indication described in
this release, that any marketing approvals, if granted, may have
significant limitations on their use, that continued approval of
such product candidate for such indication described in this
release may be contingent upon verification and description of
clinical benefit in confirmatory trials, and whether such product
candidate for such indication described in this release will be
commercially successful. Forward-looking statements in this press
release should be evaluated together with the many risks and
uncertainties that affect Bristol Myers Squibb’s business and
market, particularly those identified in the cautionary statement
and risk factors discussion in Bristol Myers Squibb’s Annual Report
on Form 10-K for the year ended December 31, 2022, as updated by
our subsequent Quarterly Reports on Form 10-Q, Current Reports on
Form 8-K and other filings with the Securities and Exchange
Commission. The forward-looking statements included in this
document are made only as of the date of this document and except
as otherwise required by applicable law, Bristol Myers Squibb
undertakes no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events, changed circumstances or otherwise.
corporatefinancial-news
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230622250207/en/
Bristol Myers Squibb
Media Inquiries: media@bms.com
Investors: investor.relations@bms.com
Bristol Myers Squibb (NYSE:BMY)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Bristol Myers Squibb (NYSE:BMY)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024